ANPCY News and Press, Angle Plc Surrey ADR From 10/17/22

GUILDFORD, UK / ACCESSWIRE / October 17, 2022 / TR-1: Standard form for notification of major holdings This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the Unite...

First regional distribution agreement for Parsortix Specialist healthcare group Promedeus appointed to distribute the Parsortix system in the Czech Republic GUILDFORD, UK / ACCESSWIRE / October 12, 2022 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biop...

ANGLE plc STUDY USING PARSORTIX DEMONSTRATES IMPORTANCE OF BIOMARKER-INDEPENDENT CTC ISOLATION IN HEAD AND NECK CANCER EMT status of CTCs found to provide additional insight to tumour tissue biopsy Potential role of CTC EMT biomarkers as therapeutic targets GUILDFORD, UK / ACCE...

ANGLE PRESENTS NEW POSTER AT AMERICAN SOCIETY FOR CLINICAL PATHOLOGY MEETING Poster describes novel use of Pap stain procedure to analyse morphology of CTCs harvested using the Parsortix system Approach could be easily implemented in standard pathology laboratory workflows GUIL...

NOVEL ASSAY DEVELOPED USING THE PARSORTIX SYSTEM ACCURATELY PREDICTS MALIGNANCY IN PELVIC MASS Publication of results from ANGLE's pelvic mass pilot study in collaboration with Wilmot Cancer Institute in a high impact journal Study informed the development of ANGLE's pelvic mass tr...

GUILDFORD, SURREY / ACCESSWIRE / June 29, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: For Frequently Used Terms, ...

BREAKTHROUGH RESEARCH WITH PARSORTIX REVEALS SPREAD OF BREAST CANCER ACCELERATES DURING SLEEP CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep Potential for optimisation of cancer care by ...

Additional contract for a new clinical trial Parsortix system to be used for longitudinal monitoring of patients with unresectable solid tumours GUILDFORD, UK / ACCESSWIRE / June 22, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to ann...

PARSORTIX SYSTEM DEMONSTRATES POTENTIAL IN PREDICTING IMMUNOTHERAPY RESPONSE IN SMALL CELL LUNG CANCER CTCs isolated by the Parsortix system can be used to evaluate PD-L1 expression Marker independent isolation of CTCs enables isolation of both EpCAM-negative and positive CTCs fr...

Prostate cancer cells may use invasive cellular protrusions to aid entry into the blood stream, a potential target in the metastatic process for novel therapy development Parsortix system isolates CTCs in 94% of prostate cancer patients, showing some association with matrix degradation ...